On December 3, 2019 Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, reported that Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. will be a featured presenter at the LD Micro Main Event on Tuesday, December 10, 2019 at 1:00 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA (Press release, Oragenics, DEC 3, 2019, View Source [SID1234551884]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Joslyn will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings.

For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

On December 3, 2019 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) a biotechnology company specializing in the development of novel treatments for brain tumors, reported that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will be participating in the 12th Annual LD Micro Main Event Conference in Los Angeles, CA (Press release, CNS Pharmaceuticals, DEC 3, 2019, https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-12th-annual-ld-micro-main-event-conference-300967894.html [SID1234551900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

12th Annual LD Micro Main Event Conference

Format:

Presentation & 1×1 Meetings

Date:

Tuesday, December 10, 2019

Time:

4:20pm PT

Location:

Luxe Sunset Boulevard Hotel, Los Angeles, CA

About Berubicin
Berubicin is an anthracycline, a class of drugs among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to damage the DNA of targeted cancer cells by interfering with the action of the topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), the world’s largest cancer research facility. Berubicin appeared to demonstrate one Durable Complete Response in a Phase I human clinical trial conducted by a prior developer.

On December 3, 2019 GO2 Foundation for Lung Cancer reported the recipients of the 2019 Young Innovators Team Awards (YITA) (Press release, Bonnie J Addario Lung Cancer Foundation, DEC 3, 2019, View Source [SID1234551868]). Two teams of researchers received grants totaling $500,000 for their work developing novel strategies to treat KRAS-mutant non-small cell lung cancer (NSCLC) and examining the impact of age on development, progression, and immunotherapy response in NSCLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The lack of institutional research funding for lung cancer creates a disincentive for talented young scientists and doctors to pursue research in this area, but we are working to change that through this partnership and joint award," said Bonnie J. Addario, lung cancer survivor, co-founder and chair of GO2 Foundation. "That is why we created the YITA – to support researchers who look beyond current methodologies of treating lung cancer."

Following a rigorous peer-review process by a panel of global lung cancer key opinion leaders, Drs. Yanxiang (Jessie) Guo and Shawn Davidson and Drs. Matthew Bott and Tuomas Tammela came out on top for their proposals titled, Targeting Tumor Metabolism to Improve Immunotherapy in KRAS-mutant NSCLC and Age-related Determinants of Initiation, Progression, and Immunotherapy Response in Non-small Cell Lung Cancer, respectively.

"These exciting proposals by talented young doctors and scientists address ongoing challenges in the field of lung cancer, bringing us closer to finding new treatments for a disease that takes more lives than colon, breast and pancreatic cancers combined," said Laurie Fenton Ambrose, co-founder, president and CEO of GO2.Foundation.

Dr. Yanxiang (Jessie) Guo from Rutgers Cancer Institute of New Jersey and Dr. Shawn Davidson from the Lewis-Sigler Institute for Integrative Genomics at Princeton University submitted the first winning proposal. Targeting Tumor Metabolism to Improve Immunotherapy in KRAS-mutant NSCLC examines the interaction of tumor cells and immune cells for growth of KRAS-driven NSCLC. To date, KRAS-mutant NSCLC has been largely resistant to most treatments. In an effort to improve outcomes and the efficacy of immunotherapy for patients with KRAS mutations, Drs. Guo and Davidson examine the metabolism of different cell types in KRAS-mutant lung tumor microenvironment to determine whether their hypothesis is correct in that cancer cell metabolism deeply affects tumor microenvironment and leads to an impaired anti-tumor immune response. The investigators’ long-term goal is to implement strategies that can overcome resistance to immunotherapy in KRAS-mutant NSCLC.

Drs. Matthew Bott and Tuomas Tammela from Memorial Sloan Kettering Cancer Center and Weill-Cornell Medical College authored the second winning proposal. Age-related Determinants of Initiation, Progression, and Immunotherapy Response in Non-small Cell Lung Cancer explores the intersection of tumor biology, anti-tumor immunity, and aging. Specifically, the investigators’ preliminary data suggest several important differences in the development and progression of lung cancer in young versus older individuals. Further, Drs. Bott and Tammela propose that lung cancer in young and older individuals represents two distinct diseases with different natural histories and susceptibilities to therapy. If true, these findings suggest the two age groups require different approaches to managing lung cancer, particularly with the use of immunotherapies that require a robust immune system.

"While we have seen recent progress in targeting KRAS, more treatment options are desperately needed. The innovative research by these two teams, particularly the proposal examining age determinants in NSCLC, complement our ongoing efforts to understand the genomics of lung cancer in patients under age 40," said Amy Moore, Ph.D., director of science and research of GO2 Foundation.

Five years ago the Bonnie J. Addario Lung Cancer Foundation (which merged with the Lung Cancer Alliance in 2019 to form GO2 Foundation for Lung Cancer) launched the Young Innovators Team Awards in partnership with the Van Auken Private Foundation. Designed to encourage out-of-the-box thinking and foster leadership skills among young innovators by instilling confidence in them to drive breakthrough lung cancer research under a collaborative, cross-institutional paradigm, YITA grants fund research that is:

Out-of-the-box – creative research that has potential for near-term benefits to lung cancer patients; high-risk, high-impact research typically not selected for federal funding
Collaborative – research that fosters collaboration among young researchers who haven’t worked together in the past, preferably across institutions
Translational – research with outcomes that can be quickly moved from the lab to the clinic, or from the bench to bedside
Multi-disciplinary – research projects that involve multiple academic disciplines/specializations in their approach to solve a problem in the field of lung cancer

On December 3, 2019 IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, reported it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells (Press release, Iontas, DEC 3, 2019, View Source [SID1234551885]). The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IONTAS’ proprietary technology enables the construction of large libraries of stable cell lines displaying human antibodies on their surface. As well as generating an abundance of therapeutic antibody leads, the technology also addresses "developability" issues early in discovery; increasing the likelihood of successful progress through the development process. Under the terms of the collaboration, the project provides Adaptate Biotherapeutics with access to IONTAS’ proprietary Mammalian Display technology, allowing the selection of high affinity antibodies based on their function, stability, expression and developability thereby facilitating a speedy transition through Chemistry, Manufacturing and Controls (CMC) and eventual manufacturing.

Dr John McCafferty, Founder and Chief Executive Officer of IONTAS, commented: "Recently spun out of GammaDelta Therapeutics, Adaptate Biotherapeutics is already a leading company in the field of gamma delta T cell therapeutics and it is a privilege to be working with such an innovative team. This collaboration is further validation of our platform, including our Mammalian Display technology, and adds to an expanding portfolio of partners that enjoy the benefit of combining selection for affinity with developability during the initial steps of drug discovery. Subsequently, the resulting panels of "developable" antibodies facilitate manufacture and reduce the risk of delays and potential product failure by detecting and avoiding problematic clones at the outset. Our aim is to ensure the right lead is selected first time, every time."

Dr Natalie Mount, Chief Executive Officer of Adaptate Biotherapeutics, said: "IONTAS has developed an impressive track record in delivering therapeutic antibodies. We selected them as our partner because of their extensive experience in overcoming antibody project challenges using their industry-leading platforms. We anticipate that the combination of IONTAS’ antibody discovery capabilities and our innovative approach to gamma delta T cell-targeted therapeutics will facilitate the accelerated entry of our oncology portfolio to the clinic."

Dr Neil Butt, Chief Business Officer of IONTAS, will be at Antibody Engineering & Therapeutics, 9–13 December 2019, San Diego, CA.

Dr John McCafferty and Dr Neil Butt will attend the 38th Annual J.P.Morgan Healthcare Conference, 13–16 January 2020, San Francisco, CA.

For further information, please visit: View Source

For a high-resolution image please contact [email protected]

On December 3, 2019 Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") reported that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicago-based institutional investor (Press release, Intech Pharmaceuticals, DEC 3, 2019, View Source [SID1234551902]). Under the terms of the Agreement, Aspire Capital is committed to purchase up to $10.0 million of Intec Pharma’s ordinary shares over a 30-month period extending into 2022, subject to certain terms and conditions. There are no warrants, derivatives, or other share classes associated with this agreement. Proceeds from the Agreement will be used to fund the Company’s research and development activites, for working capital and for general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to partner with Aspire Capital under this Agreement. Aspire Capital has been a long-term institutional shareholder in Intec Pharma and this Agreement gives us the flexibility to access capital when and if we need it. Moreover, we believe this commitment strengthens our negotiating position with any potential partners for our Parkinson’s disease program and/or for new research collaborations," stated Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "Controlling the timing and amount of ordinary shares being sold is key, as we can use this Agreement to opportunistically strengthen our balance sheet without unnecessary dilution as we seek to advance our AP platform programs to key inflection points in 2020. We appreciate Aspire Capital’s continued support."

"To us, the AP represents a major advance in drug delivery especially considering the significant number of approved and development-stage drugs that possess great therapeutic promise but remain hamstrung by either poor bioavailability or a PK profile that promotes adverse outcomes. Backed by a highly experienced management team, robust manufacturing capabilities and strong, supportive evidence from multiple clinical and non-clinical studies, the AP platform has proven to be an elegant solution for addressing these widespread drug delivery challenges. The available data, including those from the recent ACCORDANCE study, clearly demonstrate the APs ability to enhance the PK profile of drugs that have notoriously challenging absorption rates and short upper gastrointestinal residence times without sacrificing tolerability and ultimately, patient quality of life," said Steven G. Martin, Managing Member of Aspire Capital.

"The company’s collaborations with leading pharma companies such as Merck and Novartis further enhance our confidence in the AP platform’s broad applicability beyond Parkinson’s disease, where the company has already demonstrated proof-of-concept and gives us optimism about additional potential partnerships. As a result, we are thrilled to be expanding our longstanding interest and investment in Intec with this transaction," added Mr. Martin.

Under the terms of the Agreement with Aspire Capital, Intec Pharma retains full control over the timing of any stock sales made under the Agreement and the amount of stock sold to Aspire Capital. The agreement contains no restrictions on the use of proceeds, financial covenants or restrictions on future financings and no rights of first refusal, participation rights, penalties or liquidated damages. Intec Pharma maintains the right to terminate the agreement at any time, at its discretion, without any additional cost or penalty.

As consideration for Aspire Capital’s obligations under the Agreement, Intec Pharma also agreed to issue 612,520 ordinary shares to Aspire Capital as a commitment fee. Intec Pharma also entered into a Registration Rights Agreement with Aspire Capital in connection with its entry into the purchase agreement that requires Intec Pharma to file a registration statement regarding the shares sold to Aspire Capital.

For more information on the Agreement, please refer to Intec Pharma’s report on From 8-K filed today with the U.S. Securities and Exchange Commission, which can be found on the Company’s website at View Source

Intec Pharma has filed a prospectus supplement to its Form S-3 shelf registration statement (File No. 333-230016), which was declared effective on March 28, 2019 by the U.S. Securities and Exchange Commission, qualifying the offer and sale of ordinary shares to Aspire Capital. A copy of the Prospectus Supplement is available on EDGAR at www.sec.gov or may be obtained upon request to Intec Pharma.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.